HS-10296 – A Novel Third Generation EGFR Tyrosine Kinase Inhibitor: Results of the First-in-Human Phase 1 Trial in Patients with Previously Treated EGFR Mutant Advanced Non-Small-Cell Lung Cancer

Previously Treated ◽

Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.9044 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 9044-9044 ◽

Cited By ~ 25

Author(s):

Daniel Shao-Weng Tan ◽

James Chih-Hsin Yang ◽

Natasha B. Leighl ◽

Gregory J. Riely ◽

Lecia V. Sequist ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Phase 1 ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Phase 1 Study ◽

Egfr Tyrosine Kinase Inhibitor

Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu349.65 ◽

2014 ◽

Vol 25 ◽

pp. iv452

Author(s):

K. Otsuka ◽

A. Hata ◽

R. Kato ◽

J. Takeshita ◽

C. Okuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e19031 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e19031-e19031 ◽

Cited By ~ 2

Author(s):

Jair Bar ◽

Dana Botser ◽

Rossie Navon ◽

Nir Peled ◽

Haim Biran ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

Tki Resistance ◽

Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non–Small Cell Lung Cancer

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-17-1033 ◽

2018 ◽

Vol 17 (4) ◽

pp. 740-750 ◽

Cited By ~ 8

Author(s):

Toshiyuki Hirano ◽

Hiroyuki Yasuda ◽

Junko Hamamoto ◽

Shigenari Nukaga ◽

Keita Masuzawa ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Egfr Mutated ◽

Structural Characterizations

1284P MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1598 ◽

2020 ◽

Vol 31 ◽

pp. S829-S830

Author(s):

E. Felip ◽

V. Minotti ◽

R. Soo ◽

J. Wolf ◽

B. Solomon ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Met Inhibitor ◽

Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer

Molecular Medicine Reports ◽

10.3892/mmr.2020.11686 ◽

2020 ◽

Vol 23 (1) ◽

pp. 1-1

Author(s):

Yingjie Lu ◽

Dongliang Bian ◽

Xuelin Zhang ◽

Huibiao Zhang ◽

Zhenghong Zhu

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

The Third

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-17-2310 ◽

2018 ◽

Vol 24 (13) ◽

pp. 3097-3107 ◽

Cited By ~ 107

Author(s):

Zhe Yang ◽

Nong Yang ◽

Qiuxiang Ou ◽

Yi Xiang ◽

Tao Jiang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Kinase Inhibitor ◽

Resistance Mechanisms ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Lung Cancer Patients

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

SSRN Electronic Journal ◽

10.2139/ssrn.3321505 ◽

2019 ◽

Author(s):

Yi-Chen Zhang ◽

Zhi-Hong Chen ◽

Xu-Chao Zhang ◽

Chong-Rui Xu ◽

Hong-Hong Yan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Egfr T790m ◽

Clinical Strategy

A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-2595 ◽

2021 ◽

pp. clincanres.2595.2021

Author(s):

Qing Zhou ◽

Lin Wu ◽

Pei Hu ◽

Tongtong An ◽

Jianying Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Egfr T790m

A Modified Phase 1 Clinical Trial of Abivertinib (Ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

SSRN Electronic Journal ◽

10.2139/ssrn.3294124 ◽

2018 ◽

Author(s):

Qing Zhou ◽

Xiao-Qing Liu ◽

Pei Hu ◽

Jian-Ying Zhou ◽

Li Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Phase 1 ◽

Small Cell ◽

Chinese Patients ◽

Third Generation ◽

Small Cell Lung ◽

Phase 1 Clinical Trial ◽

Egfr T790m